These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1702912)

  • 21. Molecular cloning and overexpression of the human FK506-binding protein FKBP.
    Standaert RF; Galat A; Verdine GL; Schreiber SL
    Nature; 1990 Aug; 346(6285):671-4. PubMed ID: 1696686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The hepatotropic influence of cyclosporine.
    Mazzaferro V; Porter KA; Scotti-Foglieni CL; Venkataramanan R; Makowka L; Rossaro L; Francavilla A; Todo S; Van Thiel DH; Starzl TE
    Surgery; 1990 May; 107(5):533-9. PubMed ID: 2185568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expressive dysphasia possibly related to FK506 in two liver transplant recipients.
    Reyes J; Gayowski T; Fung J; Todo S; Alessiani M; Starzl TE
    Transplantation; 1990 Dec; 50(6):1043-5. PubMed ID: 1701571
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunosuppression. Binding by design.
    Ringe D
    Nature; 1991 May; 351(6323):185-6. PubMed ID: 1710317
    [No Abstract]   [Full Text] [Related]  

  • 25. Proline isomerases at the crossroads of protein folding, signal transduction, and immunosuppression.
    Heitman J; Movva NR; Hall MN
    New Biol; 1992 May; 4(5):448-60. PubMed ID: 1515410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative mutational analysis of peptidyl prolyl cis/trans isomerases: active sites of Escherichia coli trigger factor and human FKBP12.
    Tradler T; Stoller G; Rücknagel KP; Schierhorn A; Rahfeld JU; Fischer G
    FEBS Lett; 1997 Apr; 407(2):184-90. PubMed ID: 9166896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin.
    Dumont FJ; Staruch MJ; Koprak SL; Siekierka JJ; Lin CS; Harrison R; Sewell T; Kindt VM; Beattie TR; Wyvratt M
    J Exp Med; 1992 Sep; 176(3):751-60. PubMed ID: 1380976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cyclophilin and FK506-binding protein].
    Takahashi N
    Seikagaku; 1992 May; 64(5):325-31. PubMed ID: 1381737
    [No Abstract]   [Full Text] [Related]  

  • 29. Structural similarity of the binding sites of cyclophilin A-cyclosporin A and FKBP-FK506 systems.
    Denesyuk AI; Vihinen M; Lundell J; Zav'yalov VP; Korpela T
    Biochem Biophys Res Commun; 1993 Apr; 192(2):912-7. PubMed ID: 7683466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A nonimmunosuppressive triene-modified rapamycin analog is a potent inhibitor of peptidyl prolyl cis-trans isomerase.
    Ocain TD; Longhi D; Steffan RJ; Caccese RG; Sehgal SN
    Biochem Biophys Res Commun; 1993 May; 192(3):1340-6. PubMed ID: 7685167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leukocyte chemotactic activity of FKBP and inhibition by FK506.
    Leiva MC; Lyttle CR
    Biochem Biophys Res Commun; 1992 Jul; 186(2):1178-83. PubMed ID: 1379802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of cyclolinopeptide A on T lymphocyte activation and peptidyl prolyl isomerase activity.
    Gaymes TJ; Carrett NJ; Patel N; Kay JE; Siemion IZ
    Biochem Soc Trans; 1996 Feb; 24(1):90S. PubMed ID: 8674774
    [No Abstract]   [Full Text] [Related]  

  • 33. Cyclosporins: lack of correlation between antischistosomal properties and inhibition of cyclophilin isomerase activity.
    Khattab A; Pica-Mattoccia L; Klinkert MQ; Wenger R; Cioli D
    Exp Parasitol; 1998 Sep; 90(1):103-9. PubMed ID: 9709036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in peptidyl-prolyl cis/trans isomerase activity and FK506 binding protein expression following neuroprotection by FK506 in the ischemic rat brain.
    Brecht S; Schwarze K; Waetzig V; Christner C; Heiland S; Fischer G; Sartor K; Herdegen T
    Neuroscience; 2003; 120(4):1037-48. PubMed ID: 12927209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FK506 as an agonist to induce inhibition of interleukin 2 production.
    Bundick RV; Donald DK; Eady RP; Hutchinson R; Keogh RW; Schmidt JA; Wells E
    Transplantation; 1992 May; 53(5):1150-3. PubMed ID: 1374947
    [No Abstract]   [Full Text] [Related]  

  • 36. Sensitivity of mitochondrial peptidyl-prolyl cis-trans isomerase, pyridine nucleotide hydrolysis and Ca2+ release to cyclosporine A and related compounds.
    Schweizer M; Schlegel J; Baumgartner D; Richter C
    Biochem Pharmacol; 1993 Feb; 45(3):641-6. PubMed ID: 7680201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunophilins in protein folding and immunosuppression.
    Fruman DA; Burakoff SJ; Bierer BE
    FASEB J; 1994 Apr; 8(6):391-400. PubMed ID: 7513288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel peptidyl-prolyl cis/trans isomerase from Escherichia coli.
    Rahfeld JU; Schierhorn A; Mann K; Fischer G
    FEBS Lett; 1994 Apr; 343(1):65-9. PubMed ID: 8163020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nephrotoxicity of immunosuppressants in rats: comparison of macrolides with cyclosporin.
    Ryffel B; Weber E; Mihatsch MJ
    Exp Nephrol; 1994; 2(6):324-33. PubMed ID: 7532090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FK506 and the role of immunophilins in nerve regeneration.
    Gold BG
    Mol Neurobiol; 1997 Dec; 15(3):285-306. PubMed ID: 9457703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.